Kathleen Sebelius - Jun 12, 2025 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
Director
Signature
/s/ Kathleen Sebelius by Dale A. Sander as Attorney-in-Fact
Stock symbol
HUMA
Transactions as of
Jun 12, 2025
Transactions value $
$0
Form type
4
Date filed
6/16/2025, 04:30 PM
Previous filing
Apr 8, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sebelius Kathleen Director 2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM /s/ Kathleen Sebelius by Dale A. Sander as Attorney-in-Fact 2025-06-16 0001654316

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Award $0 +80K $0.00 80K Jun 12, 2025 Common Stock 80K $2.41 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029.